Aurinia Pharmaceuticals AUPH Stock
Aurinia Pharmaceuticals Price Chart
Aurinia Pharmaceuticals AUPH Financial and Trading Overview
| Aurinia Pharmaceuticals stock price | 15.67 USD |
| Previous Close | 15.33 USD |
| Open | 15.38 USD |
| Bid | 12.98 USD x 100 |
| Ask | 17.4 USD x 100 |
| Day's Range | 14.97 - 15.44 USD |
| 52 Week Range | 7.29 - 16.88 USD |
| Volume | 1.16M USD |
| Avg. Volume | 1.18M USD |
| Market Cap | 1.97B USD |
| Beta (5Y Monthly) | 1.446 |
| PE Ratio (TTM) | 7.087963 |
| EPS (TTM) | 2.16 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17 USD |
AUPH Valuation Measures
| Enterprise Value | 1.66B USD |
| Trailing P/E | 7.087963 |
| Forward P/E | 13.694097 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 6.600485 |
| Price/Book (mrq) | 3.526837 |
| Enterprise Value/Revenue | 5.57 |
| Enterprise Value/EBITDA | 10.81 |
Trading Information
Aurinia Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.446 |
| 52-Week Change | 92.58% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 16.88 USD |
| 52 Week Low | 7.29 USD |
| 50-Day Moving Average | 15.49 USD |
| 200-Day Moving Average | 14.32 USD |
AUPH Share Statistics
| Avg. Volume (3 month) | 1.18M USD |
| Avg. Daily Volume (10-Days) | 1.16M USD |
| Shares Outstanding | 128.6M |
| Float | 126.24M |
| Short Ratio | 7.56 |
| % Held by Insiders | 7.53% |
| % Held by Institutions | 59.42% |
| Shares Short | 9.02M |
| Short % of Float | 7.78% |
| Short % of Shares Outstanding | 7.01% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 99.97% |
| Operating Margin (ttm) | 53.30% |
| Gross Margin | 78.26% |
| EBITDA Margin | 51.53% |
Management Effectiveness
| Return on Assets (ttm) | 13.66% |
| Return on Equity (ttm) | 64.98% |
Income Statement
| Revenue (ttm) | 298.3M USD |
| Revenue Per Share (ttm) | 2.25 USD |
| Quarterly Revenue Growth (yoy) | 24.39% |
| Gross Profit (ttm) | 233.47M USD |
| EBITDA | 153.71M USD |
| Net Income Avi to Common (ttm) | 298.21M USD |
| Diluted EPS (ttm) | 2.16 |
| Quarterly Earnings Growth (yoy) | 47.19% |
Balance Sheet
| Total Cash (mrq) | 378.52M USD |
| Total Cash Per Share (mrq) | 2.94 USD |
| Total Debt (mrq) | 68.64M USD |
| Total Debt/Equity (mrq) | 12.09 USD |
| Current Ratio (mrq) | 5.548 |
| Book Value Per Share (mrq) | 4.341 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 166.92M USD |
| Levered Free Cash Flow (ttm) | 124.63M USD |
Profile of Aurinia Pharmaceuticals
| Country | United States |
| State | AB |
| City | Edmonton |
| Address | #140, 14315 – 118 Avenue |
| ZIP | T5L 4S6 |
| Phone | 250 744 2487 |
| Website | https://www.auriniapharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 128 |
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Q&A For Aurinia Pharmaceuticals Stock
What is a current AUPH stock price?
Aurinia Pharmaceuticals AUPH stock price today per share is 15.67 USD.
How to purchase Aurinia Pharmaceuticals stock?
You can buy AUPH shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aurinia Pharmaceuticals?
The stock symbol or ticker of Aurinia Pharmaceuticals is AUPH.
Which industry does the Aurinia Pharmaceuticals company belong to?
The Aurinia Pharmaceuticals industry is Biotechnology.
How many shares does Aurinia Pharmaceuticals have in circulation?
The max supply of Aurinia Pharmaceuticals shares is 128.6M.
What is Aurinia Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Aurinia Pharmaceuticals PE Ratio is 7.25462960 now.
What was Aurinia Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Aurinia Pharmaceuticals EPS is 2.16 USD over the trailing 12 months.
Which sector does the Aurinia Pharmaceuticals company belong to?
The Aurinia Pharmaceuticals sector is Healthcare.
Aurinia Pharmaceuticals AUPH included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Composite Total Return XCMP | 33104.2 USD — |
-0.89
|
— — | 32999.64 USD — | 33445.55 USD — | — - | — — |
| US Tech Developed ex US SC NTR G NQDMXUSSCGBPN | 1704.47 GBP 2179.91 USD |
0
|
— — | 1704.47 GBP 2179.91 USD | 1704.47 GBP 2179.91 USD | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
| US Tech Global Market Composite NQGM | 2296 USD — |
-1.38
|
— — | 2280.64 USD — | 2323.09 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}


